Quote | Pharmaxis Ltd (OTCMKTS:PMXSF)
Last: | $0.026 |
---|---|
Change Percent: | 0.0% |
Open: | $0.026 |
Close: | $0.026 |
High: | $0.026 |
Low: | $0.026 |
Volume: | 150,000 |
Last Trade Date Time: | 03/09/2023 03:00:00 am |
News | Pharmaxis Ltd (OTCMKTS:PMXSF)
(NewsDirect) Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips tells Proactive the company is set to undergo a restructure to refocus on developing drugs to treat blood-related cancers. This involves the creation of clinical stage drug development company, Syntara and the sale of its manni...
(NewsDirect) Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips speaks with Proactive after releasing data from a final interim analysis of 10 patients who have completed six months’ treatment with its drug PXS-5505 in an open label phase 2 clinical trial in patients with the bone ma...
Message Board Posts | Pharmaxis Ltd (OTCMKTS:PMXSF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Pharmaxis Ltd Company Name:
PMXSF Stock Symbol:
OTCMKTS Market:
(NewsDirect) Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips tells Proactive the company is set to undergo a restructure to refocus on developing drugs to treat blood-related cancers. This involves the creation of clinical stage drug development company, Syntara and the sale of its manni...
(NewsDirect) Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips speaks with Proactive after releasing data from a final interim analysis of 10 patients who have completed six months’ treatment with its drug PXS-5505 in an open label phase 2 clinical trial in patients with the bone ma...
(NewsDirect) Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips tells Proactive the company has made great progress towards commercialisation in a Phase 1C study of its topical Pan LOX inhibitor, achieving a well-tolerated safety profile and a marked change in scar composition. Importantly,...